PMID- 35414524
OWN - NLM
STAT- MEDLINE
DCOM- 20230822
LR  - 20230822
IS  - 1472-4146 (Electronic)
IS  - 0021-9746 (Linking)
VI  - 76
IP  - 9
DP  - 2023 Sep
TI  - MYCN amplification and International Neuroblastoma Risk Group stratification on 
      fine-needle aspiration biopsy and their correlation to survival in neuroblastoma.
PG  - 599-605
LID - 10.1136/jclinpath-2022-208177 [doi]
AB  - AIMS: Risk stratification as per the International Neuroblastoma Risk Group 
      (INRG) stratification is important for management of neuroblastoma. INRG 
      incorporates various parameters including histological category as per the 
      International Neuroblastoma Pathology Classification (INPC) and MYCN 
      amplification, which were evaluated in fine needle aspiration biopsy (FNAB) 
      samples of neuroblastoma patients to ascertain their impact in our population. 
      METHODS: This was a retrospective study including 60 neuroblastoma cases 
      diagnosed on FNAB, staged and stratified by INRG. Mitosis Karyorrhexis Index 
      (MKI), INPC morphological category and MYCN status by fluorescence in situ 
      hybridisation (n=46) were evaluated and correlated to outcome. RESULTS: The mean 
      age was 29 months (21 days to 9 years) with 27 and 33 children </>/=18 months; 
      male: female ratio of 1.6: 1; INRG stage-30(M), 20(L2), 2(L1) and 2(MS); INRG-36 
      high-risk, 13 intermediate-risk and 11 low-risk categories, respectively. MKI was 
      high, intermediate and low in 39, 4 and 7 cases, respectively. INPC morphological 
      type included 2 ganglioneuroblastomas and 58 neuroblastomas, graded further as 25 
      undifferentiated and 33 poorly differentiated tumours. MYCN was amplified in 48% 
      (22/46) cases and correlated with undifferentiated morphology (p=0.01). At a mean 
      follow-up of 469 (7-835) days, 22/50 were disease free and 28/50 had 
      relapsed/died. The overall survival correlated with age (p=0.03), stage (p=0.01), 
      INRG group (p=0.0001) and tumour grade (p=0.036). MYCN status independently did 
      not correlate with age (p=0.5), INRG stage (p=0.2) and overall survival (p=0.4). 
      CONCLUSION: FNAB is a complete modality for diagnosing neuroblastoma and 
      providing all information required for risk stratification as per INRG including 
      MKI, MYCN amplification, INPC category. Our cohort with predominant high-risk 
      neuroblastoma cases highlights regional variation.
CI  - (c) Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and 
      permissions. Published by BMJ.
FAU - Bhardwaj, Neha
AU  - Bhardwaj N
AD  - Pathology, Post Graduate Institute of Medical Education and Research, Chandigarh, 
      India.
FAU - Rohilla, Manish
AU  - Rohilla M
AD  - Cytology & Gynecological Pathology, Post Graduate Institute of Medical Education 
      and Research, Chandigarh, India.
FAU - Trehan, Amita
AU  - Trehan A
AD  - Department of Pediatrics (Hematology-Oncology Division), Post Graduate Institute 
      of Medical Education and Research, Chandigarh, India.
FAU - Bansal, Deepak
AU  - Bansal D
AD  - Department of Pediatrics (Hematology-Oncology Division), Post Graduate Institute 
      of Medical Education and Research, Chandigarh, India.
FAU - Kakkar, Nandita
AU  - Kakkar N
AD  - Histopathology, Post Graduate Institute of Medical Education and Research, 
      Chandigarh, India.
FAU - Srinivasan, Radhika
AU  - Srinivasan R
AUID- ORCID: 0000-0002-1771-091X
AD  - Cytology & Gynecological Pathology, Post Graduate Institute of Medical Education 
      and Research, Chandigarh, India drsradhika@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20220412
PL  - England
TA  - J Clin Pathol
JT  - Journal of clinical pathology
JID - 0376601
RN  - 0 (MYCN protein, human)
RN  - 0 (N-Myc Proto-Oncogene Protein)
SB  - IM
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Humans
MH  - Infant
MH  - Male
MH  - Biopsy, Fine-Needle
MH  - Gene Amplification
MH  - N-Myc Proto-Oncogene Protein/genetics
MH  - *Neuroblastoma/genetics/pathology
MH  - Prognosis
MH  - Retrospective Studies
MH  - Infant, Newborn
OTO - NOTNLM
OT  - FISH
OT  - NEUROBLASTOMA
OT  - Pathology, Molecular
COIS- Competing interests: None declared.
EDAT- 2022/04/14 06:00
MHDA- 2023/08/21 06:42
CRDT- 2022/04/13 05:33
PHST- 2022/01/20 00:00 [received]
PHST- 2022/03/25 00:00 [accepted]
PHST- 2023/08/21 06:42 [medline]
PHST- 2022/04/14 06:00 [pubmed]
PHST- 2022/04/13 05:33 [entrez]
AID - jclinpath-2022-208177 [pii]
AID - 10.1136/jclinpath-2022-208177 [doi]
PST - ppublish
SO  - J Clin Pathol. 2023 Sep;76(9):599-605. doi: 10.1136/jclinpath-2022-208177. Epub 
      2022 Apr 12.